Neoadjuvant Chemotherapy With Cabazitaxel

Inclusion Criteria: * Surgically resectable high risk prostate cancer with a 5-year relapse probability ≥ 60% according to the Kattan pre-operative nomogram (cancer 2009, 115: 1005-1010) * no prior therapy for prostate cancer such as androgen deprivation therapy, radiation therapy, or chemotherapy * ECOG performance status 0-1 * No evidence of active infection * Hemoglobin \>9.0 g/dL * Absolute neutrophil count \>1.5 x 109/L, * Platelet count \>100 x 109/L, * AST/SGOT and/or ALT/SGPT \<2.5 x ULN; * Total bilirubin \<1.0 x ULN, * Serum creatinine \<1.5 x ULN. If creatinine 1.0 - 1.5 x ULN, creatinine clearance will be calculated according to CKD-EPI formula and patients with creatinine clearance \<60 mL/min should be excluded) * Patient information and signature of informed consent * Male ≥ 18 years * Patients of reproductive age must take appropriate contraceptive precautions during and for 6 months after the end of their participation in the study Exclusion Criteria: * Evidence of lymph node, visceral or bone metastases * previous major intrapelvic surgery * previous radiation therapy to the small pelvis * any type of malignancies within the last 5 years except basalioma and non-muscle invasive urothelial cancer of the urinary bladder * previous chemotherapy with taxanes (docetaxel, paclitaxel, cabazitaxel) for any indication * Hypersensitivity to the active substance or to any of the excipients * Known or suspected brain metastases or leptomeningeal metastases * Active or symptomatic viral hepatitis or chronic liver disease * Serious or uncontrolled co-existent non-malignant disease, including active and uncontrolled infection